Business Model
YM BioSciences Inc. is a life sciences product development company advancing a diverse portfolio of promising hematology and cancer-related products at various stages of development. |
|
|
CYT387
Novel JAK1/JAK2 inhibitor for multiple indications including myeloproliferative neoplasms (MPNs) |
|
Nimotuzumab
Anti-cancer antibody that targets the epidermal growth factor receptor (EGFR) |
|
CYT997
Novel anti-cancer vascular disrupting agent (VDA) |
|
